Add to ORKGWe present the use of recombinant activated factor VIIa (rFVIIa) in a 6-month-old infant that suffered massive bleeding and subsequent coagulation disturbances during elective surgery for choroid plexus carcinoma in the lateral ventricle. The administration of rFVIIa resulted in good hemostasis. No intra- or postoperative thromboembolic complications were observed
Over the past 10 years recombinant activated factor VIIa (rFVIIa) has been successfully used for tre...
Recombinant activated factor VII (rFVIIa) has been used in the treatment of various congenital and a...
Objective—Report clinical response to recombinant factor VIIa in a cohort of critically ill infants....
We present the use of recombinant activated factor VIIa (rFVIIa) in a 6-month-old infant that suffer...
Background: The control of excessive bleeding after paediatric cardiac surgery can be challenging. T...
Bleeding complications constitute a particular challenge in neurosurgical procedures especially in c...
Recombinant factor VIIa (rFVIIa) may be useful in management of severe bleeding in paediatric oncolo...
The aim of this case series is to review the effect of recombinant activated factor VIIa (rFVIIa) on...
BACKGROUND: Patients who require extracorporeal membrane oxygenation (ECMO) postsurgery for congenit...
Recombinant human factor VIIa (rFVIIa) is approved by the US Food and Drug Administration for use in...
WOS: 000255989700005PubMed ID: 18484474Coagulopathy is an important cause of mortality in critically...
PubMedID: 18838398The literature on the use of recombinant factor VIIa (rFVIIa), which was initially...
Abstract Background Recently, there has been an increased use of recombinant activated factor VII (r...
Objective: Review the use of recombinant activated Fac-tor VII following cardiac surgery. Specifical...
Significant post-operative bleeding can be encountered in a small population of pediatric surgical p...
Over the past 10 years recombinant activated factor VIIa (rFVIIa) has been successfully used for tre...
Recombinant activated factor VII (rFVIIa) has been used in the treatment of various congenital and a...
Objective—Report clinical response to recombinant factor VIIa in a cohort of critically ill infants....
We present the use of recombinant activated factor VIIa (rFVIIa) in a 6-month-old infant that suffer...
Background: The control of excessive bleeding after paediatric cardiac surgery can be challenging. T...
Bleeding complications constitute a particular challenge in neurosurgical procedures especially in c...
Recombinant factor VIIa (rFVIIa) may be useful in management of severe bleeding in paediatric oncolo...
The aim of this case series is to review the effect of recombinant activated factor VIIa (rFVIIa) on...
BACKGROUND: Patients who require extracorporeal membrane oxygenation (ECMO) postsurgery for congenit...
Recombinant human factor VIIa (rFVIIa) is approved by the US Food and Drug Administration for use in...
WOS: 000255989700005PubMed ID: 18484474Coagulopathy is an important cause of mortality in critically...
PubMedID: 18838398The literature on the use of recombinant factor VIIa (rFVIIa), which was initially...
Abstract Background Recently, there has been an increased use of recombinant activated factor VII (r...
Objective: Review the use of recombinant activated Fac-tor VII following cardiac surgery. Specifical...
Significant post-operative bleeding can be encountered in a small population of pediatric surgical p...
Over the past 10 years recombinant activated factor VIIa (rFVIIa) has been successfully used for tre...
Recombinant activated factor VII (rFVIIa) has been used in the treatment of various congenital and a...
Objective—Report clinical response to recombinant factor VIIa in a cohort of critically ill infants....